CN1099289C - Medicinal prepn. contg. beneficial bacteria named 'Junyikang' and method for preparing same - Google Patents
Medicinal prepn. contg. beneficial bacteria named 'Junyikang' and method for preparing same Download PDFInfo
- Publication number
- CN1099289C CN1099289C CN97115093A CN97115093A CN1099289C CN 1099289 C CN1099289 C CN 1099289C CN 97115093 A CN97115093 A CN 97115093A CN 97115093 A CN97115093 A CN 97115093A CN 1099289 C CN1099289 C CN 1099289C
- Authority
- CN
- China
- Prior art keywords
- intestinal
- bifidus
- microorganism formulation
- eubiosis
- viable count
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
The present invention relates to a microbiological preparation. After one kind or more than one kind of bifidobacteria and one kind of more than one kind of intestinal tract beneficial bacteria are respectively fermented, or mixed and fermented, the bifidobacteria and the intestinal tract beneficial bacteria are matched with one kind of more than one kind of bifidus factors to make a Junyikang preparation. The bifidobacteria comprises bifidobacterium infantis, bifidobacterium longum, bifidobacterium breve, and bifidobacterium bifidum, and the intestinal tract beneficial bacteria comprises clostridium butyricum, lactobacillus acidophilus and streptococcus thermophilus. The bifidus factors mean oligosaccharide substances which have obvious promotion functions to the growth and the propagation of the bifidobacteria, or natural plant extracts, or polysaccharide substances. The preparation has the advantages that the preparation is suitable for majority of people and quickly improves the ecological balance of intestinal tracts, and has obvious therapeutic effects to dysentery and constipation.
Description
The present invention relates to a kind of microorganism formulation.
Healthy people's intestinal microbial population mainly is made up of anaerobe such as bacillus bifidus, lactobacillus, enterococcus faecalis and a spot of escherichia coli etc.Under the normal condition, the ratio of anaerobe and aerobic organism is about 400: 1, and anaerobe such as bacillus bifidus have comparative advantage.These probioticss are combined closely with intestinal epithelial cell and are constituted biological barrier on the intestinal surface, suppress the field planting growth of pathogenic bacterium, and produce lactic acid, acetic acid, and the outer glycosides enzyme of born of the same parents plays and reduces the intestinal pH value, decompose the effect of complicated polysaccharide, degraded toxin.On the contrary, if because the factor of environment, diet, medicine or microorganism causes the intestinal microbial population balance destroyed, and pathogenic bacterium breed in a large number, probiotics quantity reduces, and then will cause the function of intestinal canal disorder, and diseases such as enteritis, diarrhoea, vomiting take place.At this moment, if take antibiotics, although can control the breeding of pathogenic bacterium, probiotics has also been killed simultaneously, tended to that this thing happens, dysentery has been cured, and serious constipation has taken place again, and symptom is difficult to alleviate for a long time.In order to replenish intestinal beneficial bacterium, the scientific research people grinds and has done a large amount of work in this respect.In recent years, developed rapidly, and developed some products, and declared the patent of some this respects, but these products and patent all there are weak point at present based on the enteric microorganism preparation of bacillus bifidus, the one, mostly be single bifidobacterium preparations; The 2nd, the connection bacteria preparation is arranged, but do not contain bifidus factor; The 3rd, singly use bifidus factor.At present, single bifidobacterium preparations on the market or connection bacteria preparation product, though can play the effect that replenishes intestinal beneficial bacterium, owing to do not contain bifidus factor, growth rate is too slow.Although single bifidus factor preparation can promote the propagation of probiotics in the intestinal, Clinical Laboratory is the result show, check does not go out useful anaerobe such as bacillus bifidus in crowd's intestinal of quite a few non-health status.Particularly, the gerontal patient is even more serious, to such patient, also has few effect even take the bifidus factor preparation.
The purpose of this invention is to provide a kind of microorganism formulation and technology thereof of improving intestinal eubiosis, this product has the advantage that suitable crowd improves intestinal eubiosis extensively, rapidly.This product is obvious to the therapeutic effect of dysentery, dysentery patient then can control the breeding of pathogenic bacterium if taking this microorganism formulation that improves intestinal eubiosis treats, and has replenished, promoted growth, the propagation of probiotics simultaneously, intestinal microbial population ecology is restored balance rapidly, and the patient gets well.
For achieving the above object, the present invention takes following technical scheme: this microorganism formulation that improves intestinal eubiosis is behind the bifidobacterium fermentation with one or more, the made preparation of bifidus factor that cooperates one or more, described bacillus bifidus is selected from bifidobacteria infantis (Bifidobacteriuminfantis), CGMCC, preserve numbering 0313-2, bifidobacterium longum (Bifidobacteriumlongum), CGMCC, preserve numbering 0313-5, bifidobacterium breve (Bifidobacterium breve), CGMCC, preserve numbering 0313-6, bifidobacterium bifidum (Bifidobacterium bifidum), CGMCC, preserve numbering 0313-7, described bifidus factor is meant the growth to bacillus bifidus, the oligosaccharide substance that propagation has obvious facilitation generally passes through the glycosidic bond be combined into by 2-10 monosaccharide; Or the material of extracted form natural plant; Or polysaccharose substance, described oligosaccharide substance comprises one or more in soybean oligo saccharide, oligofructose, oligomeric xylose, oligomeric galactose, oligomeric lactulose, oligomeric isomaltose, oligomeric isomaltulose, oligomeric glucose, Raffinose, stachyose, the chitosan, its use level is dose of 0.5g-30g/, the material of described extracted form natural plant comprises one or more in Citrus pericarp extract, Radix Ginseng extract, Folium Camelliae sinensis extract, Fructus Lycii extract, the Fructus Schisandrae Chinensis extrat, and its use level is dose of 0.5g-30g/; The use level of described bacillus bifidus is 1,000 ten thousand-400,000,000/one time doses of viable count.Radix Ginseng extract wherein, Folium Camelliae sinensis extract, Fructus Lycii extract market is on sale, and Fructus Schisandrae Chinensis extrat, Citrus pericarp extract take known method to produce, and takes that water is carried, concentrated, drying makes.
Among the present invention, this microorganism formulation that improves intestinal eubiosis also adopts one or more other intestinal beneficial bacterium fermentation back formulated, and described one or more bacillus bifidus and described one or more other intestinal beneficial bacterium can ferment respectively, also can mixed culture fermentation; Described intestinal beneficial bacterium is selected from clostridium butyricum (Clostridium butyricum), CGMCC, preservation numbering 0313-1, bacillus acidophilus (Lactobacillus acidophibus), CGMCC, preservation numbering 0313-4, and streptococcus thermophilus (Streptococcus gthermophilus), CGMCC, preservation numbering 0313-3, its use level is 1,000 ten thousand-400,000,000/one time doses of viable count.
The microorganism formulation that improves intestinal eubiosis of the present invention can be used as food, health product, medicine or food additive.
The described microorganism formulation that improves intestinal eubiosis can be made into capsule, microcapsule, electuary, granule, tablet, oral liquid.Manufacturing the above-mentioned various forms of products that improve the microorganism formulation of intestinal eubiosis, all is to adopt known commonsense method to make.
In the described microorganism formulation that improves intestinal eubiosis, also be combined with various vitamin and trace element.Above-mentioned various vitamin and trace element can suitably add according to the requirement of human body.
Manufacture the bacillus bifidus that contains one or more improve intestinal eubiosis method.This microorganism formulation that improves intestinal eubiosis is made through following method:
(1) preparation fermentation medium,
(2) with culture medium under 121 ℃ of conditions, sterilized 30 minutes, when being cooled to 37 ℃, inoculate one or more bacillus bifidus, under 37 ℃ of conditions, cultivated 18 hours, the control bacteria containing amount reaches 2.2 * 10
9It is individual/as during ml, to reclaim with continuous centrifuge and to obtain wet thallus,
(3) above-mentioned wet thallus is suspended from PH is 5.6, concentration is in 20% the defatted milk powder liquid, abundant mixing, freeze-dried mycopowder, it is 4.0 * 10 that control contains viable count
10It is individual/g,
(4) above-mentioned lyophilizing mycopowder and one or more bifidus factors are by following use level mixed preparing, its use level is: the viable count of one or more bacillus bifidus is 1,000 ten thousand-400,000,000/one time doses, one or more bifidus factor is dose of 0.5g-30g/, makes the microorganism formulation that improves intestinal eubiosis at last.
Manufacture the bacillus bifidus that contains one or more, one or more Bacterium entericum, and one or more the method for improving intestinal eubiosis of bifidus factor, this method is taked bacillus bifidus and Bacterium entericum composting fermentation.This microorganism formulation that improves intestinal eubiosis is made through following method:
(1) prepares fermentation medium with distilled water, this fermentation medium contains one or more in tryptone, yeast extract, the beef extract, and oligofructose, glucose, consisting of by weight percentage of this fermentation medium: tryptone 0.5%-4%, yeast extract 0.5%-4%, beef extract 0.5%-4%, oligofructose 0.5%-4%, glucose 0.5%-4%
(2) with culture medium under 121 ℃ of conditions, sterilized 30 minutes, when being cooled to 37 ℃, inoculate one or more bacillus bifidus, with one or more intestinal beneficial bacterium, under 37 ℃ of conditions, to cultivate 18 hours, the control bacteria containing amount: the bacillus bifidus intestinal beneficial bacterium is respectively 2.2 * 10
9It is individual/as during ml, to reclaim with continuous centrifuge and to obtain wet thallus,
(3) above-mentioned wet thallus is suspended from PH is 5.6, concentration is in 20% the defatted milk powder liquid, abundant mixing, freeze-dried mycopowder, it is 4.0 * 10 that control contains viable count
10It is individual/g,
(4) above-mentioned lyophilizing mycopowder and one or more bifidus factors are by following use level mixed preparing, its use level is: the viable count of one or more bacillus bifidus is 1,000 ten thousand-400,000,000/one time doses, one or more intestinal beneficial bacterium is 1,000 ten thousand-400,000,000/doses, one or more bifidus factor is dose of 0.5g-30g/, makes the microorganism formulation that improves intestinal eubiosis at last.
Manufacture the bacillus bifidus that contains one or more, one or more Bacterium entericum, and one or more the method for improving intestinal eubiosis of bifidus factor, this method is taked bacillus bifidus and Bacterium entericum fermentation method respectively.This microorganism formulation that improves intestinal eubiosis is made through following method:
(1) prepares fermentation medium with distilled water, this fermentation medium contains one or more in tryptone, yeast extract, the beef extract, and oligofructose, glucose, consisting of by weight percentage of this fermentation medium: tryptone 0.5%-4%, yeast extract 0.5%-4%, beef extract 0.5%-4%, oligofructose 0.5%-4%, glucose 0.5%-4%
(2) with culture medium under 121 ℃ of conditions, sterilized 30 minutes, when being cooled to 37 ℃, inoculate one or more bacillus bifidus, under 37 ℃ of conditions, cultivated 18 hours, the control bacteria containing amount reaches 2.2 * 10
9It is individual/as during ml, to reclaim with continuous centrifuge and to obtain wet thallus,
(3) above-mentioned wet thallus is suspended from PH is 5.6, concentration is in 20% the defatted milk powder liquid, abundant mixing, freeze-dried mycopowder, it is 4.0 * 10 that control contains viable count
10It is individual/g,
(4) with one or more intestinal beneficial bacterium seed liquor inoculation PH be 4.5, concentration is in 10% the defatted milk powder liquid, to cultivate 14 hours under 37 ℃ of conditions, obtains the intestinal beneficial bacterium fermentation liquid, it is 2.2 * 10 that control contains viable count
9Individual/ml.
(5) wet thallus of intestinal beneficial bacterium fermentation liquid and bacillus bifidus is suspended from PH is 5.6, concentration is in 20% the defatted milk powder liquid, abundant mixing, freeze-dried lyophilizing mycopowder, it is 4.5 * 10 that control contains viable count
10It is individual/g,
(6) above-mentioned lyophilizing mycopowder and one or more bifidus factors are by following use level mixed preparing, its use level is that the viable count of the sharp intestinal beneficial bacterium of bacillus bifidus is respectively 1,000 ten thousand-400,000,000/one time doses, bifidus factor is dose of 0.5g-30g/, makes the microorganism formulation that improves intestinal eubiosis at last.
Maximum characteristics of the present invention and original creation part are, product according to the present invention produces had both contained intestinal beneficial bacteriums such as bacillus bifidus, contained the bifidus factor that promotes bifidobacterium growth propagation again, compare with product in the past, have the effect that suitable crowd improves intestinal eubiosis extensively, rapidly.The zoopery result who makes of mice shows, the microorganism formulation that improves intestinal eubiosis of the present invention is equivalent to norfloxacin to the therapeutic effect of dysentery, and does not have the side effect of norfloxacin.Norfloxacin because a large amount of probioticss are also killed, causes the intestinal microecology balance to be destroyed, and causes constipation when curing dysentery.To a little less than the 6 routine gastrointestinal functions and responsive, go on business and easily suffer from the patient of gastrointestinal dysfunction that being not acclimatized causes in the other places, begin to take the microorganism formulation that the present invention improves intestinal eubiosis at the proxima luce (prox. luc) of going on business, still continued to take 2-3 days after having arrived the other places, being not acclimatized disease disappears as a result, illustrates that gastrointestinal dysfunction, diarrheal disease that being not acclimatized is caused are effective in cure.To the gerontal patient of 3 routine habitual constipations, took the microorganism formulation that improves intestinal eubiosis of the present invention 2 days, the constipation transference cure.The constipation transference cure is the result of the loosening bowel to relieve constipation dual function of replenishing, breeding in a large number of bacillus bifidus and oligosaccharide.
Bifidus factor sees Table 1 to the facilitation of bifidobacterium growth, propagation.The result shows that different oligosaccharide and plant extract to the facilitation of bifidobacterium growth, have certain difference.Two kinds are used and are better than single usefulness.In the table 1, the composition of ordinary culture medium is to contain peptone 1%, Carnis Bovis seu Bubali cream 0.5%, and NaCl, 0.5% adds 0.5% bifidus factor on this basis, and above-mentioned each content is percetage by weight, observes the effect that promotes growth, reproduction.
Bifidus factors such as table 1 oligosaccharide are to the influence of bifidobacterium growth
| The bifidus factor kind | Addition | Promote upgrowth situation |
| Control medium (not containing bifidus factor) | 0 | + |
| Oligofructose | 0.5％ | ++++ |
| Oligomeric galactose | 0.5％ | +++ |
| Oligomeric xylose | 0.5％ | ++++ |
| Oligomeric lactulose | 0.5％ | +++ |
| Oligomeric isomaltose | 0.5％ | ++ |
| Soybean oligo saccharide | 0.5％ | +++ |
| Lycium barbarum polysaccharide | 0.5％ | ++ |
| Citrus chachiensis Hort. Chinese holly peel extract | 0.5％ | ++++ |
| Oligofructose+lycium barbarum polysaccharide | 0.25％ 0.25％ | ++++ |
| Oligomeric galactose+soybean oligo saccharide | 0.25％ 0.25％ | ++++ |
Promote upgrowth situation: visual turbidity relatively
+ growth is general; ++ well-grown; +++-++ ++ growth is significantly.
Embodiment 1 (two kinds of bacillus bifidus mixed culture fermentation)
Add 100L distilled water preparation fermentation medium.
Fermentation medium by weight percentage composed as follows: tryptone 1%, yeast extract 0.5%, beef extract 0.5%, glucose 1%, oligofructose 1%, sodium acetate 0.5%, calcium carbonate 0.05%.Under 121 ℃ of conditions, to sterilize 30 minutes, when being cooled to 37 ℃, inoculation baby and each 1L of bifidobacterium breve seed liquor under 37 ℃ of conditions, cultivated 18 hours, and bacteria containing amount reaches 2.2 * 10
9Individual/as during ml, to use continuous centrifuge, with 15000r/ minute, centrifugal recovery obtained wet thallus 0.6kg, with above-mentioned wet thallus be suspended from that 14L, PH are 5.6, concentration is in 20% the defatted milk powder liquid, abundant mixing, freeze-dried mycopowder 3kg, containing viable count is 4.0 * 10
10Individual/g.This mycopowder can be used for the microorganism formulation that improves intestinal eubiosis that different formulations is formed.The prescription composition is exemplified below:
1, lyophilizing mycopowder 2.5g.
Oligomeric galactose 2000g
Accurately take by weighing above-mentioned two kinds of components, with the abundant mixing of mixing machine, be sub-packed in 1000 bags, every bag contains bifidus factor 2g, and viable count is no less than 200,000,000.Can once take for every bag.
2, lyophilizing mycopowder 2.5g.
Oligomeric lactulose 2000g
V
c 10g
V
B1 1500mg
V
B6 1500mg
V
B12 1500mg
Z
n 1300mg
Fe 12g
Accurately take by weighing above-mentioned 8 kinds of components,, be sub-packed in 1000 bags, get final product with the abundant mixing of mixing machine.Wherein every bag contains viable count and is no less than 200,000,000.Can once take for every bag.
Embodiment 2 (butyric acid bacteria and bacillus bifidus mixed culture fermentation)
Add 100L distilled water preparation fermentation medium.
Fermentation medium by weight percentage composed as follows: tryptone 1%, yeast extract 1%, meat peptone 0.5%, glucose 1%, oligofructose 1%, sodium acetate 0.5%, calcium carbonate 0.05%.Under 121 ℃ of conditions, sterilized 30 minutes, when being cooled to 37 ℃, inoculation clostridium butyricum and each 1L of bifidobacterium longum seed liquor, under 37 ℃ of conditions, cultivated 18 hours, with 15000r/ minute, centrifugal recovery obtained wet thallus 0.6kg with continuous centrifuge, the PH that is suspended from 14L is 5.6, concentration is in 20% the defatted milk powder liquid, the fair mixing that divides, the freeze-dried mycopowder 3kg that gets, containing viable count is 4.0 * 10
10Individual/g.This mycopowder can be used for the microorganism formulation that improves intestinal eubiosis that different formulations is formed, and the prescription composition is exemplified below:
1, lyophilizing mycopowder 5g
Oligomeric xylose 1200g
V
c 10g
V
B1 1500mg
V
B6 1500mg
Z
n 1300mg
Fe 12g
Accurately take by weighing above-mentioned 7 kinds of components, fully mixing is sub-packed in 1000 bags, gets final product.Every bag contains viable count and is no less than 200,000,000.Can once take for every bag.
2, lyophilizing mycopowder 5g
Citrus chachiensis Hort. Chinese holly peel extract 500g
Oligomeric lactulose 1000g
V
c 10g
V
B1 1500mg
V
B2 1500mg
Accurately take by weighing above-mentioned six kinds of components, fully mixing is sub-packed in 1000 bags and gets final product.
Every bag contains viable count and is no less than 200,000,000.Can once take for every bag.
Embodiment 3 (divergent bacillus and bacillus acidophilus are fermented respectively, and be freeze-dried mixed)
The condition of culture of the culture medium of bacillus bifidus and recovering condition are with embodiment 1.
Bacillus acidophilus's fermentation condition be with the PH that bacillus acidophilus's seed liquor 0.2L is inoculated in 10L be 4.5, concentration is in 10% the defatted milk powder liquid, under 37 ℃ of conditions, cultivated 14 hours, recovery thalline (0.6Kg) with whole fermentation liquids and bacillus bifidus, the PH that is suspended from 10L is 6.0, concentration is in 30% the defatted milk powder liquid, abundant mixing, lyophilizing gets mycopowder 3kg, and bacteria containing amount is 4.5 * 10
10Individual/g, this lyophilizing mycopowder not only contains bacillus bifidus but also contain the bacillus acidophilus, is used to prepare the beneficial bacterium health preparation of different formulations, is exemplified below:
1, lyophilizing mycopowder 5g
Oligomeric xylose 1000g
Lycium barbarum polysaccharide 500g
V
c 10g
V
B1 1500mg
V
B6 1500mg
Accurately take by weighing above-mentioned six kinds of components, fully mixing is sub-packed in 1000 bags.Wherein every bag contains viable count and is no less than 200,000,000, can once take for every bag.
2, lyophilizing mycopowder 5g
Oligofructose 1000g
Soybean oligo saccharide 1000g
V
c 10g
V
B1 1500mg
V
B6 1500mg
Z
n 1300mg
Fe 12g
Accurately take by weighing above-mentioned 8 kinds of components, fully mixing is sub-packed in 1000 bags, gets final product.Every bag contains viable count and is no less than 200,000,000.Can once take for every bag.
The bacillus bifidus in the beneficial bacterium health preparation of the present invention and the use level of intestinal beneficial bacterium are carried out proportioning by the contained viable count of dose, and the use level of bifidus factor is to carry out proportioning by the contained weight of dose, and the microorganism formulation that improves intestinal eubiosis of all any weight of use level proportioning that proposes by the present invention is all in claim scope of the present invention.
Microorganism fungus kind used in the present invention has been put into China Committee for Culture Collection of Microorganisms common micro-organisms center (Beijing, Zhong Guan-cun, postcode 100080) preservation, totally seven following microorganism fungus kinds on July 28th, 97.
(1) classification name: Clostridium butyricum clostridium butyricum, preserve numbering 0313-1.
(2) classification name: Bifidobacterium infantis bifidobacteria infantis, preserve numbering 0313-2.
(3) classification name: Streptococcus gthermophilus streptococcus thermophilus, preserve numbering 0313-3.
(4) classification name: Lactobacillus acidophibus bacillus acidophilus, preserve numbering 0313-4.
(5) classification name: Bifidobacterium longum bifidobacterium longum, preserve numbering 0313-5.
(6) classification name: Bifidobacterium breve bifidobacterium breve, preserve numbering 0313-6.
(7) classification name: Bifidobacterium bifidum bifidobacterium bifidum, preserve numbering 0313-7.
Above-mentioned seven microorganism fungus kinds detect through this microorganism center, and testing result is survival.
Claims (8)
1, a kind of microorganism formulation that improves intestinal eubiosis, it is characterized in that: this microorganism formulation that improves intestinal eubiosis is behind the bifidobacterium fermentation with one or more, the made preparation of bifidus factor that cooperates one or more, described bacillus bifidus is selected from bifidobacteria infantis (Bifidobacteriuminfantis), CGMCC, preserve numbering 0313-2, bifidobacterium longum (Bifidobacteriumlongum), CGMCC, preserve numbering 0313-5, bifidobacterium breve (Bifidobacterium breve), CGMCC, preserve numbering 0313-6, bifidobacterium bifidum (Bifidobacterium bifidum), CGMCC, preserve numbering 0313-7, described bifidus factor is meant the growth to bacillus bifidus, the oligosaccharide substance that propagation has obvious facilitation generally passes through the glycosidic bond be combined into by 2-10 monosaccharide; Or the material of extracted form natural plant; Or polysaccharose substance, described oligosaccharide substance comprises one or more in soybean oligo saccharide, oligofructose, oligomeric xylose, oligomeric galactose, oligomeric lactulose, oligomeric isomaltose, oligomeric isomaltulose, oligomeric glucose, Raffinose, stachyose, the chitosan, its use level is dose of 0.5g-30g/, the material of described extracted form natural plant comprises one or more in Citrus pericarp extract, Radix Ginseng extract, Folium Camelliae sinensis extract, Fructus Lycii extract, the Fructus Schisandrae Chinensis extrat, and its use level is dose of 0.5g-30g/; The use level of described bacillus bifidus is 1,000 ten thousand-400,000,000/one time doses of viable count.
2, the microorganism formulation that improves intestinal eubiosis according to claim 1, it is characterized in that: this microorganism formulation that improves intestinal eubiosis also adopts one or more other intestinal beneficial bacterium fermentation back formulated, and described one or more bacillus bifidus and described one or more other intestinal beneficial bacterium can ferment respectively, also can mixed culture fermentation; Described intestinal beneficial bacterium is selected from clostridium butyricum (Clostridium butyricum), CGMCC, preservation numbering 0313-1, bacillus acidophilus (Lactobacillus acidophibus), CGMCC, preservation numbering 0313-4, and streptococcus thermophilus (Streptococcus gthermophilus), CGMCC, preservation numbering 0313-3, its use level is 1,000 ten thousand-400,000,000/one time doses of viable count.
3, the microorganism formulation that improves intestinal eubiosis according to claim 1 and 2, it is characterized in that: said preparation can be used as food, health product, medicine or food additive.
4, the microorganism formulation that improves intestinal eubiosis according to claim 1 and 2 is characterized in that: the described microorganism formulation that improves intestinal eubiosis can be made into capsule, microcapsule, electuary, granule, tablet, oral liquid.
5, the microorganism formulation that improves intestinal eubiosis according to claim 1 and 2 is characterized in that: also be combined with various vitamin and trace element in the described microorganism formulation that improves intestinal eubiosis.
6, manufacture the described a kind of production technology of improving the microorganism formulation of intestinal eubiosis of claim 1, it is characterized in that this microorganism formulation that improves intestinal eubiosis makes through following method:
(1) prepares fermentation medium with distilled water, this fermentation medium contains one or more in tryptone, yeast extract, the beef extract, and oligofructose, glucose, consisting of by weight percentage of this fermentation medium: tryptone 0.5%-4%, yeast extract 0.5%-4%, beef extract 0.5%-4%, oligofructose 0.5%-4%, glucose 0.5%-4%
(2) with culture medium under 121 ℃ of conditions, sterilized 30 minutes, when being cooled to 37 ℃, inoculate one or more bacillus bifidus, under 37 ℃ of conditions, cultivated 18 hours, the control bacteria containing amount reaches 2.2 * 10
9It is individual/as during ml, to reclaim with continuous centrifuge and to obtain wet thallus,
(3) above-mentioned wet thallus is suspended from PH is 5.6, concentration is in 20% the defatted milk powder liquid, abundant mixing, freeze-dried mycopowder, it is 4.0 * 10 that control contains viable count
10It is individual/g,
(4) above-mentioned lyophilizing mycopowder and one or more bifidus factors are by following use level mixed preparing, its use level is: the viable count of one or more bacillus bifidus is 1,000 ten thousand-400,000,000/one time doses, one or more bifidus factor is dose of 0.5g-30g/, makes the microorganism formulation that improves intestinal eubiosis at last.
7, manufacture the described a kind of production technology of improving the microorganism formulation of intestinal eubiosis of claim 2, it is characterized in that this microorganism formulation that improves intestinal eubiosis makes through following method:
(1) prepares fermentation medium with distilled water, this fermentation medium contains one or more in tryptone, yeast extract, the beef extract, and oligofructose, glucose, consisting of by weight percentage of this fermentation medium: tryptone 0.5%-4%, yeast extract 0.5%-4%, beef extract 0.5%-4%, oligofructose 0.5%-4%, glucose 0.5%-4%
(2) with culture medium under 121 ℃ of conditions, sterilized 30 minutes, when being cooled to 37 ℃, inoculate one or more bacillus bifidus, with one or more intestinal beneficial bacterium, under 37 ℃ of conditions, to cultivate 18 hours, the control bacteria containing amount: the bacillus bifidus intestinal beneficial bacterium is respectively 2.2 * 10
9It is individual/as during ml, to reclaim with continuous centrifuge and to obtain wet thallus,
(3) above-mentioned wet thallus is suspended from PH is 5.6, concentration is in 20% the defatted milk powder liquid, abundant mixing, freeze-dried mycopowder, it is 4.0 * 10 that control contains viable count
10It is individual/g,
(4) above-mentioned lyophilizing mycopowder and one or more bifidus factors are by following use level mixed preparing, its use level is: the viable count of one or more bacillus bifidus is 1,000 ten thousand-400,000,000/one time doses, one or more intestinal beneficial bacterium is 1,000 ten thousand-400,000,000/doses, one or more bifidus factor is dose of 0.5g-30g/, makes the microorganism formulation that improves intestinal eubiosis at last.
8, manufacture the described a kind of production technology of improving the microorganism formulation of intestinal eubiosis of claim 2, it is characterized in that this microorganism formulation that improves intestinal eubiosis makes through following method:
(1) prepares fermentation medium with distilled water, this fermentation medium contains one or more in tryptone, yeast extract, the beef extract, and oligofructose, glucose, consisting of by weight percentage of this fermentation medium: tryptone 0.5%-4%, yeast extract 0.5%-4%, beef extract 0.5%-4%, oligofructose 0.5%-4%, glucose 0.5%-4%
(2) with culture medium under 121 ℃ of conditions, sterilized 30 minutes, when being cooled to 37 ℃, inoculate one or more bacillus bifidus, under 37 ℃ of conditions, cultivated 18 hours, it is to reach 2.2 * 10 that control contains bacterium
9It is individual/as during ml, to reclaim with continuous centrifuge and to obtain wet thallus,
(3) above-mentioned wet thallus is suspended from PH is 5.6, concentration is in 20% the defatted milk powder liquid, abundant mixing, freeze-dried mycopowder, it is 4.0 * 10 that control contains viable count
10It is individual/g,
(4) with one or more intestinal beneficial bacterium seed liquor inoculation PH be 4.5, concentration is in 10% the defatted milk powder liquid, to cultivate 14 hours under 37 ℃ of conditions, obtains the intestinal beneficial bacterium fermentation liquid, it is 2.2 * 10 that control contains viable count
9Individual/ml.
(5) wet thallus of intestinal beneficial bacterium fermentation liquid and bacillus bifidus is suspended from PH is 5.6, concentration is in 20% the defatted milk powder liquid, abundant mixing, freeze-dried lyophilizing mycopowder, it is 4.5 * 10 that control contains viable count
10It is individual/g,
(6) above-mentioned lyophilizing mycopowder and one or more bifidus factors are by following use level mixed preparing, its use level is that the viable count of bacillus bifidus and intestinal beneficial bacterium is respectively 1,000 ten thousand-400,000,000/one time doses, bifidus factor is dose of 0.5g-30g/, makes the microorganism formulation that improves intestinal eubiosis at last.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN97115093A CN1099289C (en) | 1997-08-01 | 1997-08-01 | Medicinal prepn. contg. beneficial bacteria named 'Junyikang' and method for preparing same |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN97115093A CN1099289C (en) | 1997-08-01 | 1997-08-01 | Medicinal prepn. contg. beneficial bacteria named 'Junyikang' and method for preparing same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1192360A CN1192360A (en) | 1998-09-09 |
| CN1099289C true CN1099289C (en) | 2003-01-22 |
Family
ID=5173112
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN97115093A Expired - Lifetime CN1099289C (en) | 1997-08-01 | 1997-08-01 | Medicinal prepn. contg. beneficial bacteria named 'Junyikang' and method for preparing same |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1099289C (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108741088A (en) * | 2018-05-29 | 2018-11-06 | 广州富诺营养科技有限公司 | Heat-resisting probiotic composition and health food comprising the composition |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1273838A (en) * | 2000-04-26 | 2000-11-22 | 济南三株药业有限公司 | Nutritive composition containing symbiotic fermentation culture medium of dead probiotics |
| EP1384483A1 (en) * | 2002-07-23 | 2004-01-28 | Nestec S.A. | Probiotics for treatment of irritable bowel disease (IBS) through improvement of gut neuromuscular function |
| SE526711C2 (en) * | 2003-01-31 | 2005-10-25 | Probi Ab | New strains of Bifidobacterium capable of survival in the gastrointestinal tract and produce glutamine in vivo, as well as compositions and uses thereof |
| PL1675481T3 (en) * | 2003-10-24 | 2009-03-31 | Nutricia Nv | Synbiotic composition for infants |
| EP1776877A1 (en) * | 2005-10-21 | 2007-04-25 | N.V. Nutricia | Method for stimulating the intestinal flora |
| CN101314763B (en) * | 2007-06-01 | 2011-06-08 | 统一企业(中国)投资有限公司 | Short bifidobacteria with functions of anti-gastrointestinal tract pathogen, oxidation resistance and blood pressure reduction and its uses |
| CN101336938B (en) * | 2007-07-02 | 2012-08-29 | 青岛东海药业有限公司 | Use of probiotics in preparing composition for treating and preventing hand-foot-mouth disease |
| CN101449830B (en) * | 2008-12-29 | 2012-01-11 | 山东龙力生物科技股份有限公司 | Mid-aged milk powder added with biostime and preparation method thereof |
| CN101711582B (en) * | 2009-08-28 | 2012-08-22 | 上海交大昂立股份有限公司 | Composition containing American ginseng extract and probiotics and application thereof |
| CN102090558A (en) * | 2010-12-09 | 2011-06-15 | 上海交大昂立股份有限公司 | Composition containing probiotics, DHA (docosahexaenoic acid) and lactoferrin and applications thereof |
| CN102727530A (en) * | 2012-04-30 | 2012-10-17 | 威海康博尔生物药业有限公司 | Combination and application of probiotics and related prebiotics |
| CN102952771B (en) * | 2012-11-19 | 2013-12-25 | 陕西科技大学 | Streptococcus thermophilus freeze-drying protective agent and preparation method thereof |
| CN102960599A (en) * | 2012-11-19 | 2013-03-13 | 陕西科技大学 | Method for preparing bifidobacterium microcapsules containing prebiotics |
| CN104415061B (en) * | 2013-08-30 | 2016-06-01 | 深圳华大基因科技有限公司 | Edible composition and its production and use |
| CN103653170B (en) * | 2013-11-21 | 2015-06-10 | 威海百合生物技术股份有限公司 | Stachyose probiotics solid beverage |
| CN104107194A (en) * | 2014-04-09 | 2014-10-22 | 南昌大学 | Making method of human intestinal micro-ecological system |
| CN104489646B (en) * | 2014-11-19 | 2016-08-31 | 李雅君 | A kind of fruit and vegerable probiotic tablet and preparation method thereof |
| CN104489462B (en) * | 2014-12-09 | 2017-12-29 | 山东龙力生物科技股份有限公司 | A kind of xylo-oligosaccharide probiotic powder |
| CN104957617A (en) * | 2015-06-30 | 2015-10-07 | 钟训艳 | Stachys probiotic composition |
| CN107022501A (en) * | 2016-05-03 | 2017-08-08 | 深圳市儿童医院 | Application of the bifidobacterium infantis in food hypersenstivity food or medicine is prevented and treated |
| CN107095885A (en) * | 2017-04-28 | 2017-08-29 | 青岛东海药业有限公司 | Application of the clostridium butyricum in prevention or treatment COPD preparation is prepared |
| CN108669563A (en) * | 2018-03-30 | 2018-10-19 | 北京斯利安药业有限公司 | A kind of composition, its application and strengthen immunity, the product for improving allergy |
| CN111956676A (en) * | 2020-08-24 | 2020-11-20 | 天津现代创新中药科技有限公司 | A microecological preparation containing Ginseng radix extract and probiotic bacteria, and its preparation method and application |
| CN113005066B (en) * | 2021-03-31 | 2023-07-21 | 江苏蓝泽生物科技有限公司 | Compound bifidobacterium preparation for resisting allergy, increasing immunity, reducing blood sugar and fat and losing weight and preparation method thereof |
| CN113424965A (en) * | 2021-06-29 | 2021-09-24 | 镇江远森医药科技有限公司 | Microecological preparation more suitable for yellow population |
| CN114437996B (en) * | 2022-03-25 | 2024-03-15 | 广西医科大学第一附属医院 | Heat-inactivated clostridium butyricum for preventing or treating asthma and preparation method thereof |
| CN114916676B (en) * | 2022-06-21 | 2024-05-28 | 河南省商业科学研究所有限责任公司 | Microencapsulated probiotics containing stachyose and konjac powder and preparation method thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1103584A (en) * | 1993-12-10 | 1995-06-14 | 济南高新开发区克立医药生物研究所 | Sanzhu oral liquid and its preparing method |
| CN1112012A (en) * | 1995-03-08 | 1995-11-22 | 河北神力医药保健品厂 | Biological oral liquid |
| CN1114354A (en) * | 1994-06-23 | 1996-01-03 | 江苏省纺织(集团)总公司实业开发分公司 | Aerobic fermentation process for Bifidobacterium in Chinese-medicinal culture medium |
| CN1132636A (en) * | 1995-04-05 | 1996-10-09 | 王世荣 | Ecological liubao oral liquid |
-
1997
- 1997-08-01 CN CN97115093A patent/CN1099289C/en not_active Expired - Lifetime
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1103584A (en) * | 1993-12-10 | 1995-06-14 | 济南高新开发区克立医药生物研究所 | Sanzhu oral liquid and its preparing method |
| CN1114354A (en) * | 1994-06-23 | 1996-01-03 | 江苏省纺织(集团)总公司实业开发分公司 | Aerobic fermentation process for Bifidobacterium in Chinese-medicinal culture medium |
| CN1112012A (en) * | 1995-03-08 | 1995-11-22 | 河北神力医药保健品厂 | Biological oral liquid |
| CN1132636A (en) * | 1995-04-05 | 1996-10-09 | 王世荣 | Ecological liubao oral liquid |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108741088A (en) * | 2018-05-29 | 2018-11-06 | 广州富诺营养科技有限公司 | Heat-resisting probiotic composition and health food comprising the composition |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1192360A (en) | 1998-09-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1099289C (en) | Medicinal prepn. contg. beneficial bacteria named 'Junyikang' and method for preparing same | |
| CN1663573B (en) | A stable and safe microecological formulation, its preparation and usage | |
| CN102366023B (en) | Method for preparing cow feed additive containing traditional Chinese medicine active probiotics | |
| CN1119154C (en) | Live triple bifidobacteria preparation and preparing method thereof | |
| JP5000066B2 (en) | Conversion and modification of natural drugs by co-fermentative culture of intestinal symbiotic organisms | |
| CN102318806B (en) | Preparation method of probiotics fermented pumpkin and carrot vegetable powder | |
| CN108991327A (en) | A kind of probiotics solid beverage and preparation method thereof | |
| CN110179121A (en) | It is a kind of to improve the 5-linked probiotic composition of enteron aisle, compound solid beverage and its preparation method and application | |
| CN1843385A (en) | Enteral microecological formulation and its preparation process | |
| CN105641209A (en) | Probiotics composition with function of improving immunity and preparing method and application of probiotics composition | |
| CN1480528A (en) | Bifidobacteria and preparations containing them | |
| CN1273838A (en) | Nutritive composition containing symbiotic fermentation culture medium of dead probiotics | |
| CN105018408B (en) | It is a kind of to add the method that rutin promotes growth of probiotics in the medium | |
| CN101560523B (en) | Nutrient composition based on mixed fermented culture of five probiotics | |
| CN107397042A (en) | A kind of composite type animal enteron aisle regulation preparation and preparation method thereof | |
| CN106754619A (en) | It is a kind of that the method that traditional Chinese medicinal components promote growth of probiotics is added in grain culture medium | |
| CN109528814B (en) | Microecological preparation of lactobacillus fermented astragalus membranaceus as well as preparation method and application of microecological preparation | |
| CN109315769A (en) | It is a kind of for improving the composition and preparation method thereof of human body enteral environment | |
| CN117204573B (en) | Composite prebiotic concentrate with effect of improving intestinal health and preparation method and application thereof | |
| CN108785331A (en) | It is a kind of that there is qi-blood tonifying composition and its preparation method and application | |
| CN106417989A (en) | Probiotic composition for aquatic animal feed, preparation method and application thereof | |
| US20240342225A1 (en) | Combined formulation capable of ameliorating gastrointestinal adverse effects caused by oxaliplatin and preparation method therefor and use thereof | |
| CN101406489A (en) | Micro-ecological complex bacterial agent and method of preparing micro-ecological complex bacterial agent | |
| CN110200186B (en) | Probiotic solid beverage and preparation method thereof | |
| CN113142302B (en) | Probiotic yogurt with blood glucose reducing effect and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1037052 Country of ref document: HK |
|
| EE01 | Entry into force of recordation of patent licensing contract |
Assignee: Qingdao Eastsea Pharmaceutical Co., Ltd. Assignor: Dongfanghaixin Biological Technology Co., Ltdd., Beijing Contract fulfillment period: 2007.8.30 to 2017.8.1 contract change Contract record no.: 2008370000095 Denomination of invention: Medicinal prepn. contg. beneficial bacteria named 'Junyikang' and method for preparing same Granted publication date: 20030122 License type: Exclusive license Record date: 2008.11.6 |
|
| LIC | Patent licence contract for exploitation submitted for record |
Free format text: EXCLUSIVE LICENSE; TIME LIMIT OF IMPLEMENTING CONTACT: 2007.8.30 TO 2017.8.1; CHANGE OF CONTRACT Name of requester: QINGDAO DONGHAI PHARMACY CO., LTD. Effective date: 20081106 |
|
| ASS | Succession or assignment of patent right |
Owner name: BEIJING POURKANG MEDICINE HIGH SCIENCE AND TECHNOL Free format text: FORMER OWNER: BEIJING DONGFANGBAIXIN BIOISYSTECH CO., LTD. Effective date: 20091106 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20091106 Address after: Beijing City, Haidian District Fuchengmen Road, Bai duizi (No. 131 Fucheng Road middle school building 5, room 101) Patentee after: Beijing Puerkang Medical High Technology Co., Ltd. Address before: Beijing City, Haidian District Bai duizi Fuchengmen Road No. 131 Patentee before: Dongfanghaixin Biological Technology Co., Ltdd., Beijing |
|
| CX01 | Expiry of patent term |
Granted publication date: 20030122 |
|
| CX01 | Expiry of patent term |